GlassScriptPhysician profile
Liana Nikolaenko
NPI 1700124914
$687.77
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $73.00 · 2021: $355 · 2022: $144.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $177.45 | 2021 | |
| Seagen INC. | $144.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $124.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $102.90 | 2019 | |
| Beigene USA, INC. | $94.14 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $32.35 | 2021 | |
| Janssen Biotech, INC. | $12.68 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Research and ownership
$2,000.20 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liana Nikolaenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.